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Objectives. This study aimed to evaluate the effect of menopausal status on the risk of metabolic syndrome (MetS) in Tunisian
women. Methods. We analyzed a total of 2680 women aged between 35 and 70 years. Blood pressure, anthropometric indices,
fasting glucose, and lipid profile were measured. The MetS was assessed by the modified NCEP-ATPIII definition. Results. The
mean values of waist circumference, blood pressure, plasma lipids, and fasting glucose were significantly higher in postmenopausal
than in premenopausal women, a difference that was no longer present when adjusting for age. Except for hypertriglyceridaemia,
the frequency of central obesity, hyperglycemia, high blood pressure, and high total cholesterol was significantly higher in
postmenopausal than in premenopausal women. After adjusting for age, the significance persisted only for hyperglycemia.
The overall prevalence of MetS was 35.9%, higher in postmenopausal (45.7% versus 25.6%) than in premenopausal women. A
binary logistic regression analysis showed that menopause was independently associated with MetS (OR= 1.41, 95% CI 1.10–1.82)
after adjusting for age, residence area, marital status, family history of cardiovascular disease, education level, and occupation.
Conclusions. The present study provides evidence that the MetS is highly prevalent in this group of women. Menopause can be a
predictor of MetS independent of age in Tunisian women.
1. Introduction
The metabolic syndrome (MetS) has been identified as
a constellation of metabolic and nonmetabolic disorders
related to defects in insulin sensitivity that lead to a high risk
for the development of type 2 diabetes and cardiovascular
disease (CVD) [1].TheMetS is considered a problem of world
proportions affecting both developed and underdeveloped
countries in a rapidly progressive way [2–4]. The prevalence
in different countries, nevertheless, varies considerably. Dif-
ferences in genetic profile, eating habits, level of physical
activity, age, gender, and lifestyle influence the prevalence of
MetS and its components [5]. The prevalence of MetS varies
also according to the characteristics of the population studied
and the diagnostic criteria adopted [6]. It has been suggested
that menopause is a contributing factor for this change
in prevalence [7]. Menopause with its incidental hormonal
changes appears to increase the risk of CVD independently
of normal aging, and premenopausal women may be pro-
tected against CVD comparedwithmen and postmenopausal
women of a similar age [8]. Estrogen deficiency appears to
be associated with an increased risk for the development of
most of the clinical features comprising MetS [9]. Whether
menopause has a casual effect on MetS is unclear. Few
studies have investigated the effect of menopause on the
development of the MetS independent of age [7, 10–12]. As
there is no Tunisian report available concerning this subject,
we undertook the present study to determine the prevalence
of MetS and its components in pre- and postmenopausal
women, as well as the association between the menopausal
status and MetS.
2. Methods
2.1. Sampling. A total of 8007 individuals (mean age ± SD,
49.6 ± 9.7 years, range: 35–74 years; 3417 men (49.6 ± 9.8
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years), 4590 women (49.5 ± 9.6 years)) were enrolled from
a national Tunisian survey conducted from April 2004 to
September 2005. The subjects were selected using two-stage
stratified cluster sampling of households.The sampling frame
was derived by the Tunisian National Institute of Statistics
from the database of the 2004 census of the population;
in each stratum 47 census districts were selected, with
a probability proportional to size in number of eligible
households (i.e., featuring at least one 35–74 years old house-
hold resident). At the second stage, 25 eligible households
were sampled in each district; then for each household, all
household residents from the targeted age range were to be
included during the implementation of the field survey. This
survey was integrated in a collaborative project funded by the
European Commission to study epidemiological Transition
and Health Impact in North Africa (TAHINA). The overall
response rate was 79.5%; rates were generally lower in urban
than rural areas and in men than in women. The study
protocol was carried out according to the Declaration of
Helsinki and has been ethically approved by the Tunisian
Ministry of Health and the Tunisian National Council of
Statistics (visa n∘5/2005). All participants gave their free
informed consent, after being thoroughly informed on the
purpose, requirement, and procedures of the survey.
Among the 4590 women, participants who had one or
moremissing values of the risk factors necessary for a diagno-
sis of MetS were excluded, leaving 2814 persons. We excluded
also smoker subjects because of the limited size of this group
(42) and in order to eliminate the possible implication of
smoking in the relationship between menopause and MS.
For the analysis of the effect of menopause, we excluded
those who had missing data regarding menopause, including
premature menopause induced by surgery, chemotherapy,
or radiation (62), and those who currently used hormone
replacement therapy (HRT) (30).These exclusions were done
in order to homogenize data for all participants. Ultimately, a
total of 2680 (58%) women, aged 35–74 years, were included
in the present study. They were divided in two groups:
premenopausal and postmenopausal women. Menopause is
defined as amenorrhea for the 12 months following the final
menstrual period [13]. In our study postmenopausal women
were defined as women with natural menopause whose
current age was ≥1 year than their age of menopause and who
did not receive HRT.
2.2. Data Collection. During the course of the interview,
trained research nurses had to complete a questionnaire
that contained data on sociodemographic characteristics
including age, residence area, marital status, education level,
occupation, smoking, and family medical history of CVD.
A family history of CVD was defined as having at least one
parent or sibling diagnosed with hypertension, stroke, or
coronary heart disease. The age and the time elapses after
menopausewere included in the questionnaire.Marital status
was categorized as single, married, widowed, or divorced.
Educationwas classified into four categories: level 0: illiterate;
level 1: low-level education (≤6 years of schooling); level 2:
intermediate-level education (7–13 years of schooling); and
level 3: higher education (≥14 years of schooling). Occupation
was classified into two categories: employed and unemployed.
2.3. Measurements. Anthropometric measurements includ-
ing weight and height were taken with the subjects’ barefoot
and wearing light clothing. Waist circumference (WC) was
measured in the erect position at the middle between the
tenth rib and the iliac crest. Body mass index (BMI) was
calculated as the ratio of weight (kg) to the square of the
height (m2). Systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were measured twice by mercury sphygmo-
manometer in the sitting position after they had been quietly
seated for more than 15min. The mean of the two measure-
ments was used in the analyses. Blood samples were collected
after a 12-hour overnight fast. Fasting plasma glucose (FPG)
was determined by the glucose oxidase enzymatic method.
Serum triglycerides (TG) were measured enzymatically after
hydrolyzation of glycerol and total-cholesterol (TC) was
measured by the cholesterol oxidase enzymatic method. All
biochemical analyses were done using a Beckman reagent kit
on a Beckman SYNCHRON CX7 analyzer.
2.4. Definition of the MetS. The National Cholesterol Educa-
tion ProgramAdult Treatment Panel III (NCEP-ATPIII) clin-
ical definition of the MetS requires the presence of three or
more of the following criteria:WC≥ 102 cm inmen or≥88 cm
in women, TG ≥ 1.7mmol/L, HDL-C < 1.03mmol/L in men
or <1.29mmol/L in women, SBP ≥ 130mmHg and/or DBP ≥
85mmHg, and FPG ≥ 6.1mmol/L [14]. In the present study
HDL-cholesterol (HDL-C)was not determined because at the
time of the survey themethod of dosage was the precipitation
method, which was known for its large variability, and serum
was not kept to measure it. Since TC has been shown to be
directly related to mortality from coronary heart diseases,
even in populations with low cholesterol concentrations [15],
we used TC instead of HDL-C as previously reported [16–
19]. The cut-off point used for TC was ≥5.2mmol/L in men
and women. Subjects who reported taking hypertension or
diabetes medications were considered to have elevated BP or
high FPG, respectively.
2.5. Statistical Analysis. Data are presented as mean (SD) for
continuous variables and as number (percentage) for categor-
ical variables. Differences in baseline characteristics between
groups were analyzed by Student’s t-test and 𝜒2 test for
continuous variables and categorical variables, respectively.
Associations of quantitative variables withmenopausal status
were examined by analysis of covariance (General Linear
Model procedure) adjusting for age. The age-adjusted odds
ratios (ORs) for risk factors for the MetS were calculated
by logistic regression with age as a continuous variable. The
relationship between the menopausal status and MetS was
observed in a simple logistic regression model, with the OR
and its confidence interval (CI) being estimated at 95%.
Multivariate logistic regression analysis was used to assess
the independent contribution of menopausal status to the
presence of the MetS with an adjustment for age, residence
area, marital status, family history of CVD, occupation, and
education level. Data analysis was performed using the SPSS
statistical package for Windows (version 15.0, SPSS, Chicago,
IL, USA), and 𝑃 value of less than 0.05 was considered
significant.
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3. Results
Anthropometric and biological characteristics of the study
population stratified by menopausal status are presented in
Table 1. The participants were between 35 and 74 years old,
including 1311 (48.9%) premenopausal womenwithmean age
42.9 ± 5.0 years and 1369 (51.1%) postmenopausal women
with mean age 57.5 ± 7.3 years. In addition to significantly
higher age, postmenopausal women also had higher mean
values of WC, SBP and DBP, and plasma TC, TG, and FPG
compared to premenopausal women. After adjustment for
age, the difference was no longer present.
The prevalence of theMetS and its components among all
study participants and by menopausal status are summarized
in Table 2. In all population, the most frequent component
of MetS was high WC followed by high TG, high BP, high
TC, and high FPG. Except for high TG, the prevalence of
the other MetS components was significantly higher among
postmenopausal women. However, when these factors were
adjusted for age, the significance persisted only for high FPG.
The overall prevalence ofMetSwas 35.9%. Prevalence ofMetS
amongst postmenopausal women was significantly higher
than that in premenopausal women (45.7% versus 25.6%,
𝑃 < 0.001).
Table 3 showed the ORs for MetS after adjustment for
age groups, residence area, marital status, family history of
CVD, education level, occupation, and menopausal status.
The unadjusted and multivariate-adjusted ORs for the MetS
in postmenopausal women were 2.45 and 1.41, respectively
(95% CI 2.08–2.89 and 1.10–1.82, resp.) compared with
premenopausal women. Multiple logistic regression analysis
revealed that oldest age; urban area and widowed/divorced
status were associated with increased ORs for the MetS.
However, the multivariate model showed that family history
of CVD, education level, and occupation were not associated
with the MetS. In the multivariate analysis, when age was
included as a continuous variable, the relationship between
menopause and MetS remained statistically significant (OR
= 1.42, 95% CI 1.10–1.84, 𝑃 = 0.006).
Since the prevalence of MetS increases with age and due
to the higher collinearity between age andmenopausal status,
we added a subgroup analysis on the women aged 45 to
54 for better clarifying the association between menopause
and the occurrence of MetS. In this subgroup (𝑛 = 922),
postmenopausal women (𝑛 = 521) had higher prevalence
of MetS (42.8% versus 35.7%, 𝑃 = 0.028) compared to
premenopausal women (𝑛 = 401). In comparison to the
premenopausal stage, the OR (95% CI) for MetS was 1.35
(1.03–1.76) for postmenopausal stage. In amultivariatemodel,
adjusting for possible confounding factors, menopause was
independently associated with MetS (OR = 1.39, 95% CI
1.05–1.84, 𝑃 = 0.020), and this association was unchanged
after adjusting for age. Urban residence was significantly
associated with the occurrence of MetS in univariate and
multivariate logistic regressions (Table 4).
4. Discussion
Today, CVD is one of the main causes of mortality of
women in the world [20]. Various studies have shown that
Table 1: Differences in anthropometric and biological parameters
between pre- and postmenopausal women.
Variables Premenopausal Postmenopausal 𝑃 value
Women (𝑛 = 1311) Women (𝑛 = 1369)
Age (years) 42.9 (5.0) 57.5 (7.3) <0.001
BMI (kg/m2) 29.4 (9.3) 28.9 (10.5) 0.253
WC (cm) 91.7 (13.1) 93.7 (13.3) <0.001
SBP (mmHg) 123.7 (17.2) 136.5 (22.1) <0.001
DBP (mmHg) 74.4 (11.0) 80.5 (12.8) <0.001
FPG (mmol/L) 4.71 (1.41) 5.30 (2.09) <0.001
TC (mmol/L) 4.41 (0.98) 4.66 (1.03) <0.001
TG (mmol/L) 1.94 (1.05) 2.02 (1.12) 0.048
Data are presented as mean (SD) and were compared by 𝑡-test. BMI: body
mass index; WC: waist circumference; SBP: systolic blood pressure; DBP:
diastolic blood pressure; FPG: fasting plasma glucose; TC: total cholesterol;
TG: triglycerides.
being affected by MetS increases the risk of CVD as well
as morbidity of the disease [21, 22]. On the other hand,
menopause with its incidental hormonal changes appears to
increase the risk of CVD independently of normal aging,
and premenopausal women may be protected against CVD
compared withmen and postmenopausal women of a similar
age [8]. The relationship between menopause and MetS is
controversial [8]. Rarer still are those that associate MetS
with menopause. This lack of data, plus the importance of
MetS as a cardiovascular risk factor, encouraged us to conduct
this study, which was intended to determine the prevalence
of MetS and its components in premenopausal and post-
menopausal women, as well as the association between the
menopausal status and MetS.
The overall prevalence of MetS in this study was 35.9%.
Such data are consistent with those reported in a recent study
carried out in the Tunisian population [3]. To the best of our
knowledge, our study is the first to demonstrate the effect
of menopause on the MetS in a representative population of
Tunisian women. We found that the prevalence of MetS was
significantly higher among postmenopausal women (45.7%)
than among premenopausal women (25.6%).There is current
controversy on whether MetS worsens with age alone or
as a result of menopausal transition. In the present study,
the prevalence of MetS increased with age. This finding was
statistically significant in both univariate and multivariate
analyses. In addition to the significant effect of age on the risk
of MetS, the multivariate model showed that urban area was
significantly associated with an increased risk of the MetS.
Our findings showed also that the risk of MetS increased
among widowed and divorced women compared to married
women and that could be explained by the fact that married
women are more likely to engage in positive health behaviors
than widowed and divorced women [23].
With respect to menopausal status, a binary logistic
regression analysis showed that postmenopausal stage was
associated with an increased risk of the MetS adjusting for
confounding variables such as age, residence area,marital sta-
tus, family history of CVD, education level, and occupation.
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Table 2: Prevalence of the metabolic syndrome and its components among all study participants and by menopausal status.
All subjects
𝑛 (%)
Premenopausal
𝑛 (%)
Postmenopausal
𝑛 (%) 𝑃 value
MetS components
High WC 1768 (66.0) 830 (63.3) 938 (68.5) 0.004
High BP 1359 (50.7) 473 (36.1) 886 (64.7) <0.001
High FPG 345 (12.9) 103 (7.9) 242 (17.7) <0.001
High TC 599 (22.4) 221 (16.9) 378 (27.6) <0.001
High TG 1410 (52.6) 673 (51.3) 737 (53.8) 0.195
MetS 961 (35.9) 335 (25.6) 626 (45.7) <0.001
WC: waist circumference; BP: blood pressure; FPG: fasting plasma glucose; TC: total cholesterol; TG: triglycerides.
Table 3: Unadjusted and adjusted odds ratio for the metabolic syndrome as dependent variable and the associated factors as independent
variables among all study participants.
𝑛 (% MetS) Unadjusted
a
OR (95% CI) 𝑃 value
a Adjustedb
OR (95% CI) 𝑃 value
b
Age (years)
35–44 930 (21.0) 1 1
45–54 922 (39.7) 2.48 (2.02–3.04) <0.001 2.06 (1.60–2.65) <0.001
55–64 532 (46.8) 3.31 (2.62–4.18) <0.001 2.39 (1.70–3.37) <0.001
65–74 296 (51.0) 3.92 (2.97–5.17) <0.001 2.88 (1.96–4.24) <0.001
Residence area
Rural 1130 (29.2) 1 1
Urban 1550 (40.7) 1.66 (1.41–1.96) <0.001 1.79 (1.49–2.14) <0.001
Marital status
Married 2205 (33.8) 1 1
Single 61 (37.7) 1.18 (0.70–2.00) 0.524 1.25 (0.71–2.19) 0.428
Widowed/divorced 414 (46.6) 1.71 (1.38–2.11) <0.001 1.26 (1.00–1.59) 0.043
Family history of CVD
No 2592 (35.4) 1 1
Yes 75 (52.0) 1.97 (1.24–3. 13) 0.004 1.39 (0.85–2.28) 0.178
Education level
Illiterate 1527 (37.7) 1 1
Lower 804 (35.3) 0.90 (0.75–1.07) 0.254 1.21 (0.98–1.49) 0.077
Medium 282 (29.8) 0.70 (0.53–0.92) 0.011 0.91 (0.66–1.25) 0.584
Higher 60 (23.3) 0.50 (0.27–0.92) 0.026 0.74 (0.37–1.48) 0.405
Occupation
Employed 322 (30.1) 1 1
Unemployed 2287 (37.0) 1.36 (1.06–1.75) 0.016 0.86 (0.64–1.15) 0.312
Menopause status
Premenopausal 1311 (25.6) 1 1
Postmenopausal 1369 (45.7) 2.45 (2.08–2.89) <0.001 1.41 (1.10–1.82) 0.007
OR: odds ratio; CI: confidence interval; MetS: metabolic syndrome; CVD: cardiovascular disease.
aUnivariate logistic regression.
bMultivariate logistic regression analysis including MetS as the dependent variable and age groups, residence area, marital status, family history of CVD,
educational level, occupation, and menopause status as independent variables.
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Table 4: Unadjusted and adjusted odds ratio for the metabolic syndrome as dependent variable and the associated factors as independent
variables among participants aged 45 to 54 years.
𝑛 (% MetS) Unadjusted
a
OR (95% CI) 𝑃 value
a Adjustedb
OR (95% CI) 𝑃 value
b
Residence area
Rural 384 (34.6) 1 1
Urban 538 (43.3) 1.44 (1.10–1.89) 0.008 1.49 (1.11–1.99) 0.007
Marital status
Married 767 (39.1) 1 1
Single 15 (33.3) 0.77 (0.26–2.29) 0.650 0.61 (0.19–2.01) 0.427
Widowed/divorced 140 (43.6) 1.20 (0.83–1.73) 0.322 1.16 (0.79–1.71) 0.422
Family history of CVD
No 20 (50.0) 1 1
Yes 898 (39.5) 1.53 (0.63–3.71) 0.348 1.42 (0.56–3.58) 0.452
Education level
Illiterate 485 (38.1) 1 1
Lower 326 (42.0) 1.17 (0.88–1.56) 0.268 1.14 (0.84–1.55) 0.391
Medium 94 (38.3) 1.00 (0.63–1.58) 0.978 0.95 (0.58–1.55) 0.845
Higher 15 (40.0) 1.08 (0.37–3.08) 0.884 1.11 (0.36–3.38) 0.845
Occupation
Employed 123 (35.8) 1 1
Unemployed 770 (41.0) 1.25 (0.84–1.85) 0.270 1.36 (0.89–2.10) 0.151
Menopause status
Premenopausal 401 (35.7) 1 1
Postmenopausal 521 (42.8) 1.35 (1.03–1.76) 0.028 1.39 (1.05–1.84) 0.020
OR: odds ratio; CI: confidence interval; MetS: metabolic syndrome; CVD: cardiovascular disease.
aUnivariate logistic regression.
bMultivariate logistic regression analysis including MetS as the dependent variable and residence area, marital status, family history of CVD, educational level,
occupation, and menopause status as independent variables.
To clarify the relationship between menopausal status
and MetS, and to minimize the high collinearity between
age and menopause, we focused our analyses in a smaller
sample of women who are in similar age range. We analysed
the subgroup of women aged 45–54 years. We found that
the prevalence of MetS remained significantly increased in
postmenopausal women and that the risk of MetS increased
with postmenopausal stage, even after adjusting for possi-
ble confounding factors. These results are consistent with
Korean, US, and Iranian studies [7, 10–12]. In contrast, other
studies reported that postmenopausal women had higher
prevalence of the MetS than premenopausal women, but this
difference disappeared when adjusted for age [24–27]; the
authors mentioned that the main risk factor for the increase
in the prevalence of MetS was age [26].
Our finding adds to the growing body of evidence
implicating menopause as a predictor of MetS independent
of age. The mechanisms underlying the association between
menopausal transition and MetS have not fully been elu-
cidated. The decline in ovarian function is considered the
main cause of this phenomenon [9]. A nine-year cohort
study in various ethnic groups demonstrated that 13.7% of
women were affected by MetS in menopause period and all
components of MetS changed significantly in the studied
women after menopause. This study demonstrated that the
occurrence of MetS in postmenopausal women was the
result of testosterone hormone secretion and change in all
components of MetS [11]. It has been recently reported
that menopause is closely related to insulin resistance and
cardiovascular risk factors [12].
Although it is commonly believed that menopause is
associated with weight gain, most studies do not reveal
increases in BMI independent of normal aging [7, 12]. How-
ever, even in the absence of weight gain, body fat distribution
changes across the menopause. Cross-sectional [28] and
longitudinal studies [11] have shown that the menopausal
transition is associated with a preferential increase in abdom-
inal adiposity, independent of the effect of age and total
body adiposity. In the present study we failed to detect an
association between anthropometric measurements includ-
ing BMI andWC and menopause result similar to that found
in other studies [12, 26, 29]. The influence of menopause on
BP is difficult to evaluate because menopause coincides with
aging [30]. Some studies have reported a strong association
between BP and menopause, but other studies have not
[30, 31]. We found that mean SBP and DBP did not differ
significantly between pre- and postmenopausal women after
adjusting for age.
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Menopause was found to be associated with an increase
in TC and TG levels [32, 33] and a decrease in HDL-C
[8, 34]. However, not all studies [8, 12, 29, 35] agree with
this conclusion. In our study, variation in plasma lipid profile
during menopause transition was age dependent. Increase
in FPG in postmenopausal women has been reported [36],
whereas other studies reported no significant changes in FPG
levels between pre- and postmenopausal women [7, 29]; these
findings are in accordance with our result.
Change in the rate of MetS components during
menopausal transition is controversial [7, 12, 29]. Our
findings showed no significant difference in the rate of
MetS components across menopausal status adjusting for
age except of hyperglycemia. It may be partly due to aging,
but this alone cannot explain the rapid acceleration in
the rate of MetS suffered by women during menopause
[9]. In our population, the risk of MetS increased in
postmenopausal period, even excluding the effect of age
and other confounding factors. The absence of significant
difference in incidence of MetS components except one
of them between the two menopausal stages suggests that
besides the aforementioned factors, other effective factors
such as genetic or environmental ones contribute to the
pathogenesis of the disease, which shows their effect in
various ethnic groups differently.
Our study has strengths and limitations. The strengths
include the large sample consisting of both urban and rural
populations, a sound representation of the national popu-
lation, and detailed information on potential confounding
factors. As a cross-sectional study, the present analysis, how-
ever, is limited in its ability to elucidate a causal relationship.
Another limitation was the absence of the measurement of
HDL-C as explained above. Additionally, selection biasmight
have occurred during the exclusion of ineligible women.
5. Conclusion
Thepresent study showed a high prevalence ofMetS amongst
women above 35 years of age. The MetS was more prevalent
amongst postmenopausal women and the significance per-
sisted when adjusted for age and other confounding factors.
Although there was an independent association between
menopausal status and the prevalence of MetS, further
prospective studies are needed to confirm menopause as a
risk factor for developing MetS.
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